Biogen stock stays strong with Outperform rating as Oppenheimer highlights disciplined growth strategy By Investing.com
On Wednesday, Biogen Inc. (NASDAQ:), currently trading at $143.26 with a market capitalization of $20.9 billion, maintained its positive outlook from Oppenheimer, with the firm reiterating an Outperform rating and a $255.00 price target for the company’s shares.
According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculations. The endorsement follows a recent meeting with Biogen’s management, during which several key strategies and priorities were discussed for the year 2025.
The company’s commercial strategies are set to enhance the uptake of Leqembi, including alternative dosing schema and partnerships for the development of non-invasive diagnostics centered around brain biomarkers (BBM). With a…
